Answers are grounded in this paper and cite their sources.
The in vitro activity of iclaprim, a novel diaminopyrimidine derivative, was evaluated against 5,937 recent gram-positive clinical isolates collected in the United States and Europe. Iclaprim demonstrated potent activity against Staphylococcus aureus (including methicillin-resistant S. aureus [MRSA]), beta-hemolytic Streptococcus spp., and Enterococcus faecalis strains tested. In addition, iclaprim exhibited bactericidal activity against all S. aureus strains tested, including MRSA.
No takes yet. Share an insight, caveat, or question.
Sader et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: